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Detection of erythropoietin in human liquor: Intrinsic erythropoietin
production in the brain. Until now, erythropoietin (EPO) was thought to
he produced exclusively in fetal liver and adult kidney and to regulate
mammalian erythropoiesis. However, we recently showed that steady state
levels of EPO mRNA could be induced up to 100-fold in primary mouse
astrocytes cultured under hypoxic conditions, and also reported the
presence of mRNA for EPO and its receptor in the brain of mouse,
monkey and human. In extending these studies on humans we now show
that immunoreactive EPO is present in ventricular cerebrospinal fluid
(CSF) of 5 patients with traumatic brain injuries: EPO was found in 15 Out
of 15 CSF samples. There was no correlation between the serum EPO
Concentration and the concentration in the CSF. However, EPO concen-
trations in CSF correlated with the degree of blood-brain-barrier dysfunc-
tion. This suggests that EPO does not cross the intact blood-brain-harrier,
implying that EPO is produced in the brain itself, most probably by
astroeytcs in an oxygen-dependent manner. In view that neuronal cells
carry the EPO receptor, we propose that EPO acts in a paracrine fashion
in the central nervous system and might function as a protective factor
against hypoxia-induced damage of neurons.
Erythropoietin (EPO) is a glycoprotein growth factor that has
been known as the main regulator of erythropoiesis by preventing
apoptosis of erythroid progenitor cells [1]. EPO is produced
mainly in fetal liver and adult kidney. Peritubular interstitial
fibroblasts have been identified as EPO-producing cells in the
kidney [2], whereas in the liver, both hepatocytes and the non-
parenchymal Ito cells have been found to express EPO [3, 4].
However, several other organs such as brain, testis, lung, spleen,
and placenta [5—81 as well as the embryonic stem cell-derived
embryoid bodies [91 have been shown to express EPO [10]. In
particular, we and others showed that primary cultures of astro-
cytes were a source of brain-derived EPO [7, 11]. EPO mRNA
levels in the brain of mice could he stimulated by inducing anemia
in the animals [6, 11] and isolated primary astrocytes increased
their EPO mRNA expression when exposed to low oxygen. We
further showed that the mRNA for EPO and its receptor were
expressed in the brain of monkey and humans [11]. In addition,
clinical observations detecting EPO in human tumors of the
central nervous system (CNS), such as cerebellar heniangioblas-
toma [12] and meningioma [13] implied that EPO is produced in
the brain.
The number of cytokines found to be expressed in the brain is
steadily increasing [14] and a thorough study of their expression
pattern will allow delineation of their function in the complex
network of the CNS. In the case of EPO, however, despite
detection of oxygen-regulated EPO mRNA in the brain in vivo
and of bioactive EPO protein in cultured primary astrocytes [6, 7,
11], the presence of EPO protein in the CNS has not been shown
so far. Therefore, we investigated whether EPO protein was
detectable in human cerebrospinal fluid (CSF) collected from
patients suffering from isolated traumatic brain injury. Insertion
of indwelling ventricular catheters (IVC) allowed monitoring and
treatment of their elevated intracranial pressure. This therapeutic
approach enabled us to measure EPO in the CSF and in corre-
sponding serum samples.
Methods
Patients
All 5 patients (1 female, 4 male; mean age 42.2 14.7 years,
range 25 to 59 years) with the primary diagnosis of head injury
included in this study have been described previously [151. All of
them received indwelling ventricular catheters (IVC) for contin-
uous intracranial pressure monitoring. After surgery, the patients
were treated according to standardized protocols [15].
Serum and cerebrospinal fluid sampling
CSF samples (9 ml) were drained at different days via IVC,
collected over 24 hours and kept at 4°C until centrifugation at
170 >< g for 10 minutes. Following concentration with Centriprep
30 (Amicon) at 4°C, the samples were stored at —70°C. Blood
samples were taken at the same time points as the CSF collection.
Serum was centrifuged at 170 >< g for 10 minutes at 4°C and
frozen at —70°C until analyzed. EPO concentration in CSF and
serum was determined using a radioimmunoassay as described
[16]. Hemoglobin content was measured by photometric analysis
at 420 nm wavelength.
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Blood-brain-barrier Jhnction
As a sensitive parameter for blood-brain-harrier (BBB) dys-
function, the CSF/serum albumin ration (QA) was calculated. The
disturbance of the BBB permeability was evaluated as follows: QA
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Sample Patient Age/sex QA
1 A 59/rn 0.0143' 33.7 1.43
2 A 0.0203a 37.0 1.21
3 A 0.0024 37.8 1.08
4 A 0.0044 35.7 1.23
5 A 0.0049 34.8 1.18
6 B 41/m 0.0028 34.3 1.01
7 B 0.0039 40.3 1.01
8 B 0.0026 32.2 0.94
9 C 25/w 0.0017 40.7 1.25
10 C 0.0022 36.7 1.21
11 C 0.0014 36.2 1.17
12 D 31/rn 0.0310a 41.8 1.75
13 D 0.0286 32.8 1.62
14 E 55/rn 0.0338' 32.9 1.80
15 E 0.0140 32.8 1.23
Fifteen samples of CSF and serum were taken at different days from 5
patients with brain injury.
In 6 samples a moderate to severe disturbance of BBB function was
observed (QA > 0.007), whereas no dysfunction was evident in the other
nine samples.
EPO concentrations (U/liter) were determined in duplicate by radioim-
munoassay. Abbreviation QA is the CSF/serurn albumin ratio.
values below 0.007 were regarded as a normal BBB function,
values between 0.007 and 0.01 were regarded as a sign of a mild
disturbance, values between 0.01 and 0.02 as moderate distur-
bance, and values above 0.02 as severe BBB dysfunction [15].
Analysis of data
Statistical analysis was performed on commercially available
software (PRISM 2.0; GraphPad Software Inc., San Diego, CA,
USA) using Student's t-test and Pearson's correlation coefficient.
A statistical probability of P < 0.05 was considered significant.
Unless indicated otherwise, means are expressed with the corre-
sponding SD.
Results and discussion
Immunoreactive EPO is present in human CSF
Blood and CSF samples were collected at various days from 5
patients and EPO levels were determined by radioimmunoassay
(Table 1). Collection of CSF through the ventricular catheter had
the advantage that contamination with blood, often occurring
when CSF is asserved by lumbal puncture, was minimized. To
further exclude blood contamination, hemoglobin content in CSF
was measured by photometric analysis and compared to the levels
found in the corresponding serum samples. Hemoglobin levels in
CSF were barely detectable and at least six orders of magnitude
lower than levels found in serum (data not shown), thus excluding
any significant contamination. Immunoreactive EPO was found in
all 15 CSF samples tested (Table 1). The mean concentration in
CSF was 1.27 0.26 U/liter, while 35.9 3.5 U/liter were found
in the serum. EPO found in CSF could originate from brain tissue
itself. On the other hand, a possible leakage of the BBB could
allow the passage of EPO from the periphery into the CNS. To
assess the integrity of the BBB function, the CSF/serum albumin
ratio (QA) was determined (Methods). In six samples from 3
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Fig. 1. EPO levels in semm and CSF do not correlate. EPO concentrations
in serum and CSF of 5 patients with isolated traumatic brain injury were
grouped according to their corresponding albumin ratio QA, a sensitive
parameter for BBB function. No significant correlation was found when
the BBB showed either no (A) (r = 0.36; P = 0.34) or moderate/severe (B)(r = 0.19; P = 0.72) dysfunction. Abbreviations are: CSF, cerebrospinal
fluid; BBB, blood-brain-barrier.
patients a moderate to severe disturbance of the BBB was evident,
while in the other nine samples the BBB was intact with 0A <
0.007 (Table 1).
Intrinsic production of EPO in brain tissue
To evaluate if there was a relation between the levels of EPO in
CNS and serum, we next analyzed and compared the values with
the albumin quotient. EPO values in CSF and serum were
grouped according to their corresponding QA. No correlation
between EPO in both fluids was found (Fig. 1). However, when
EPO levels in CSF were compared with the degree of BBB
dysfunction, a clear correlation was evident (r = 0.89; P < 0.0001;
Fig. 2). EPO levels in CSF increased from 1.12 0.11 U/liter
(N = 9) in samples with normal BBB function to 1.33 (N =2) and
1.60 0.27 (N = 4) U/liter, respectively, when BBB function was
moderately or severely disturbed.
Table 1. Patient data
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Fig. 2. EPO levels in CSF con-elate with BBB dysfirnction. EPO concen-
trations in CSF of all 15 samples wcre correlated to their corresponding
albumin ratio °A A significant correlation (Pearson's test) was apparent
(r 0.89; P < 0.0001).
protective factor against hypoxia-induced damage of neurons.
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Taken together, these results suggest that serum EPO can only
cross an impaired BBB. On the other hand, these findings imply
that EPO found in CSF of patients with normal BBB function is
most probably produced in the brain itself. Indeed, we and others
have previously shown that EPO mRNA is present in the brain of
rodents and primates and that astrocytes express EPO in an
oxygen-dependent manner [5, 7, 11]. At present, the physiological
function of EPO in the nervous system is unknown. In vivo
experiments have demonstrated that EPO prolongs the survival of
lesioned neurons after fimbria-fornix transections in rats [17].
Furthermore, EPO augmented choline acetyltransferase activity
in mouse embryonic primary septal neurons [17] and increased
monoamine and calcium levels in PC12 cells, which carry the EPO
receptor [18]. In view that we have found expression of the EPO
receptor also in mouse and primate brain [11], and EPO binding
sites in various regions of the mouse brain [61, and localized EPO
receptors on neuronal cells (M. Digicaylioglu, H.H. Marti, C.
Bauer; unpublished data), we propose that EPO might act in a
paracrine fashion in the central nervous system, perhaps as a
